Young D B, Duncan K
Department of Medical Microbiology, St Mary's Hospital Medical School, Imperial College, London, United Kingdom.
Annu Rev Microbiol. 1995;49:641-73. doi: 10.1146/annurev.mi.49.100195.003233.
Mycobacterium tuberculosis claims more lives each year than any other single human pathogen. Despite the availability of effective drugs, the incidence of tuberculosis is increasing in much of the developing world and has recently reemerged as a public health problem in industrialized countries. In the first section of this chapter, current understanding of the fundamental biology of mycobacterial infection is reviewed from the perspective of development of new tools for disease control. A second section describes strategies for identification of novel antimycobacterial agents, with particular emphasis on recent progress in defining biosynthetic pathways for unique mycobacterial cell wall components. The third section focuses on current approaches to the development of new vaccine candidates consisting of live attenuated bacteria or individual antigenic subunits.
每年，结核分枝杆菌夺走的生命比其他任何单一人类病原体都要多。尽管有有效的药物，但结核病在许多发展中国家的发病率仍在上升，并且最近在工业化国家再度成为一个公共卫生问题。在本章的第一部分，我们从开发疾病控制新工具的角度回顾了目前对分枝杆菌感染基本生物学的认识。第二部分描述了鉴定新型抗分枝杆菌药物的策略，特别强调了在确定独特分枝杆菌细胞壁成分的生物合成途径方面的最新进展。第三部分重点介绍了目前开发新型候选疫苗的方法，这些疫苗包括减毒活细菌或单个抗原亚单位。
